Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenacapavir in Heavily Treatment Experienced People Living With HIV-1 Infection With Multidrug Resistance
NCT04150068Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Nov 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of lenacapavir in human immunodeficiency virus type 1 infection (HIV-1) (3 cohorts), sponsored by Gilead Sciences. Primary endpoint: Reduction of >= 0.5 log10 Copies/mL in HIV-1 RNA at Day 15. Started Nov 2019; status: active, not recruiting.
02
Drugs
lenacapavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04150068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04150068.